Vuba aha, GenFleet Therapeuticsbyatangajwe n’Ikigo gishinzwe imiti (ISAF) mu Karere k’Ubushinwa gashinzwe imiyoborere yihariye ya Macau, cyemeje Dupert® (fulzerasib, GFH925/IBI351) ku kuvura abarwayi barwaye kanseri y’ibihaha itari iy’uturemangingo duto (NSCLC) bafite KRAS G12C mutation, bakaba barahawe nibura ubuvuzi bumwe bwo mu mubiri.
Fulzerasib ni yo miti ya mbere ya KRAS G12C yakozwe n’Ubushinwa yemejwe na NMPA mu rwego rwo kugenzura isuzuma ry’ibanze muri Kanama 2024.
Ku bijyanye na Dupert® (fulzerasib, KRAS G12C Inhibitor)
Byavumbuwe na GenFleet Therapeutics, fulzerasib (GFH925/IBI351) ni umuti mushya, ukora mu kanwa, kandi ukomeye wa KRAS G12C ugamije kwibasira neza ihererekanya rya GTP/GDP, intambwe y'ingenzi mu gukora inzira, binyuze mu guhindura ibisigazwa bya cysteine bya poroteyine ya KRAS G12C mu buryo buhuriweho kandi butavaho. Inyigo zakozwe mbere yo gusuzuma cysteine zagaragaje ko GFH925 ihitamo cyane kuri G12C. Nyuma yaho, GFH925 ibuza neza inzira y'ikimenyetso yo hasi kugira ngo itere apoptosis y'uturemangingo tw'ikibyimba no guhagarika uruhererekane rw'uturemangingo.
Fulzerasib kandi yahawe inama yo mu cyiciro cya mbere mu kuvura KRAS G12C-mutant NSCLC mu mabwiriza ya CSCO yo mu 2025, aha abarwayi uburyo bushya bwo kuvura burambye kandi bushobora kwihanganirwa.
Dukurikije imibare y’icyiciro cya kabiri cy’ubushakashatsi bwo kwiyandikisha mu barwayi ba KRAS G12C mutant NSCLC, fulzerasib monotherapy yageze kuri ORR ya 49.1% n’impuzandengo ya PFS yageze ku mezi 9.7; igipimo cya OS cy’amezi 12 cyari 54.4%, naho igipimo cya DoR cy’amezi 12 cyari 53.7%. Iyi monotherapy yahawe kandi imyanya ibiri yo kuvura indwara ya kanseri y’inkondo y’umura ya KRAS G12C iteye imbere ndetse n’abarwayi ba kanseri y’inkondo y’umura.
Iyobowe na GenFleet ku bufatanye n'inzobere zikomeye mu kurwanya kanseri y'ibihaha zo mu Burayi, inyigo ya KROCUS kuri fulzerasib hamwe na cetuximab yanatanze umusaruro utangaje ku barwayi bose ba NSCLC bo ku rwego rwa mbere, cyane cyane igisubizo kidasanzwe ku barwayi banduye kanseri mu bwonko. Byongeye kandi, iyi gahunda yagaragaje umutekano mwiza/kwihanganirwa kurusha fulzerasib monotherapy mu kuvura NSCLC yo ku rwego rwa kabiri no hejuru yayo. Nk'uruvange rw'ibanze rw'umuti ubuza KRAS G12C (fulzerasib) n'umuti urwanya EGFR antibody (cetuximab) mu kuvura kanseri y'ibihaha yo ku rwego rwa mbere, ubu buryo bushya bufite ubushobozi bwo gushyiraho SOC y'ikisekuru gitaha yo kuvura NSCLC yo ku rwego rwa mbere.
Dukurikije amakuru ari mu nyandiko yasohotse mu kiganiro gito cyo mu nama ngarukamwaka y’inama ngarukamwaka y’Umuryango w’Ubumwe bw’u Burayi ku ndwara ya kanseri y’ibihaha (ELCC) yo mu 2025, abantu 45 mu bitabiriye igerageza bakoze isuzuma rya kanseri nyuma yo kuvurwa ku ya 14 Mutarama 2025: ORR yageze kuri 80%; DCR yageze kuri 100%; mPFS yari amezi 12.5.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Igihe cyo kohereza: 15 Nyakanga-2025